Experimental pill for pancreatic cancer hailed as biggest breakthrough in decades
A new pill called daraxonrasib is being described as the most significant advance against pancreatic cancer in decades. The drug targets the RAS protein family, which is mutated in the large majority of pancreatic tumours. The Guardian report, published 20 November 2026, frames the development as a major step for a disease with historically poor survival rates. The source material provided is limited to the article link and discussion metadata, so details of trial results and availability could not be verified here. Readers are advised to consult the full Guardian article for clinical specifics.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.
Discussion (0)
Log in to join the discussion and vote.
Log in